Video Experimental Relacionado
Updated: May 5, 2026
09:33
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.6K
Caminos hacia y lejos de la enfermedad de Alzheimer
1Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, 5600 Nathan Shock Drive, Baltimore, Maryland 21224, USA. mattsonm@grc.nia.nih.gov
Nature
|August 6, 2004
Resumen
La enfermedad de Alzheimer (EA) causa pérdida de memoria y deterioro cognitivo al dañar las células nerviosas. Comprender los cambios moleculares en la enfermedad de Alzheimer puede conducir a nuevos tratamientos para detener o revertir la neurodegeneración.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Patología Patología Patología.
- Farmacología Farmacología.
Sus antecedentes:
- La enfermedad de Alzheimer (EA) es un trastorno neurodegenerativo progresivo caracterizado por pérdida de memoria y deterioro cognitivo.
- La enfermedad resulta de la disfunción y muerte de las neuronas cruciales para el procesamiento de la información.
- Los tratamientos actuales ofrecen solo un alivio sintomático temporal, sin la capacidad de detener o revertir la progresión de la enfermedad.
Objetivo del estudio:
- Para resumir la comprensión actual de la patogénesis de la enfermedad de Alzheimer.
- Para resaltar la necesidad de nuevas estrategias terapéuticas dirigidas a los procesos neurodegenerativos subyacentes.
- Hacer hincapié en el potencial de los avances recientes en la investigación celular y molecular para el desarrollo de intervenciones efectivas.
Principales métodos:
- Revisión de la literatura existente sobre la enfermedad de Alzheimer.
- Análisis de los mecanismos celulares y moleculares subyacentes a la neurodegeneración en el Alzheimer.
- Síntesis de las tendencias actuales de la investigación en la terapia de AD.
Principales resultados:
- La enfermedad de Alzheimer implica la disfunción neuronal progresiva y la muerte, lo que lleva a graves cambios cognitivos y de personalidad.
- Las intervenciones farmacéuticas existentes proporcionan solo una mejora de la memoria transitoria.
- Se están logrando avances significativos en la comprensión de la base molecular de la muerte neuronal en la enfermedad de Alzheimer.
Conclusiones:
- Se necesitan con urgencia estrategias preventivas y terapéuticas efectivas para la enfermedad de Alzheimer.
- La investigación continua sobre las alteraciones celulares y moleculares en la enfermedad de Alzheimer es crucial.
- Los avances en la comprensión de los mecanismos de la enfermedad ofrecen esperanza para futuros tratamientos que puedan detener o revertir la neurodegeneración.
Videos de Conceptos Relacionados
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
01:23Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
01:24Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35